<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00570999</url>
  </required_header>
  <id_info>
    <org_study_id>EudraCt: 2007-003241-32</org_study_id>
    <nct_id>NCT00570999</nct_id>
  </id_info>
  <brief_title>Palifermin After Haploidentical PBSCT</brief_title>
  <acronym>KGF Haplo Allo</acronym>
  <official_title>Randomised Placebo-Controlled Double-Blind Phase II Study Applying Palifermin to Improve T-cell Immune Reconstitution After Haploidentical Allogeneic Peripheral Blood Progenitor Cell (PBPC) Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Society for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Society for Blood and Marrow Transplantation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blind, placebo controlled clinical trial, where patients with an advanced&#xD;
      form of blood cancer are treated with haploidentical allogeneic peripheral blood progenitor&#xD;
      cell (PBPC) transplant after which they are randomised to receive either placebo or a&#xD;
      keratinocyte growth factor (Palifermin or Kepivance®).&#xD;
&#xD;
      The function of Kepivance® is to stimulate the growth of epithelial cells. This drug has also&#xD;
      been suggested to have an ability to help improve the reconstitution, or development, of the&#xD;
      immune system after the transplantation.&#xD;
&#xD;
      The hypothesis is that the patients T-cell dependent humoral immune response to recall&#xD;
      antigen (PrevenarTM) will be higher in in palifermin treated patients than in the placebo&#xD;
      control group&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Anticipated">January 2013</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To test palifermin's effect on the T-cell dependent humoral immune response to recall antigen (Prevenar™)</measure>
    <time_frame>at study day +270 (20 days after the third Prevenar injection)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation</measure>
    <time_frame>at study days: +240</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess if Palifermin improves T-cell reconstitution after haploidentical allogeneic transplantation</measure>
    <time_frame>Study days +210, +240, +270</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess disease free survival (DFS) and overall survival (OS), incidence and duration of GvHD, incidence and severity of OM, and incidence and severity of infections</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess drug related safety</measure>
    <time_frame>at 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Non-Hodgkin's Lymphoma or Hodgkin's Disease</condition>
  <condition>Acute Leukaemia</condition>
  <condition>Myelodysplastic Syndrome</condition>
  <condition>Chronic Myeloid Leukemia</condition>
  <condition>Osteomyelofibrosis</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Palifermin once daily at a dose of 60 mg/kg/day for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo at a dose of 1.2 mL (saline 0,9%) once daily for 3 days before the start of the conditioning regimen and then for 3 consecutive days starting on the day of transplantation (days 0 to day +2 inclusively).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Palifermin</intervention_name>
    <description>60 mg/kg/day</description>
    <arm_group_label>Arm A</arm_group_label>
    <other_name>Keratinocyte growth factor</other_name>
    <other_name>Kepivacine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1,2 mL once daily</description>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>0.9% saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Recipient:&#xD;
&#xD;
          -  Chemosensitive low/high grade B-NHL or T-NHL, Multiple Myeloma (MM) in partial or&#xD;
             complete remission&#xD;
&#xD;
          -  ALL and AML, secondary AML and biphenotypic acute leukemia in complete remission (CR1&#xD;
             or CR2) or PR (only if ≤20% blasts in BM), Myelodysplastic syndrome (MDS)&#xD;
&#xD;
          -  CML in chronic or accelerated phase&#xD;
&#xD;
          -  Osteomyelofibrosis (OMF)&#xD;
&#xD;
          -  Hodgkin lymphoma (HD) in partial or complete remission&#xD;
&#xD;
          -  Age ≥18 years, ≤ 65 years&#xD;
&#xD;
          -  ECOG status ≤2&#xD;
&#xD;
          -  Prior treatment with 3 or less different chemotherapy regimens (not cycles); prior&#xD;
             local radiotherapy is allowed except radiation involving the thymus&#xD;
&#xD;
          -  Adequate pulmonary function&#xD;
&#xD;
          -  Left ventricular ejection fraction (LVEF) &gt;30%&#xD;
&#xD;
          -  Haploidentical related donor&#xD;
&#xD;
          -  Failure to find matched related or matched unrelated donor and urgently requiring&#xD;
             transplantation&#xD;
&#xD;
          -  Planned conditioning regimen per Aversa or Würzburg protocol&#xD;
&#xD;
          -  Women must be post-menopausal, sterile or use effective contraception and have a&#xD;
             negative pregnancy test at study entry (β-HCG neg)&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Donor:&#xD;
&#xD;
          -  Healthy family member&#xD;
&#xD;
          -  Selection based on typing of HLA-A, B, C, DR loci. Donor must be at least&#xD;
             genotypically HLA-A, B, C, DR haploidentical to the patient, but must differ for 2-3&#xD;
             HLA allele(s) on the unshared haplotype&#xD;
&#xD;
          -  Donors must be capable of undergoing leukapheresis, have adequate venous access, and&#xD;
             be willing to undergo insertion of a central venous catheter should leukapheresis via&#xD;
             peripheral vein be inadequate.&#xD;
&#xD;
          -  Donors must agree to a 2nd donation of PBPCs in case of insufficient CD34+ cell&#xD;
             collection or should patient fail to demonstrate sustained engraftment&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Recipient:&#xD;
&#xD;
          -  History of or concurrent cancer (&lt; 5 years ago) other than those named in inclusion&#xD;
             criteria&#xD;
&#xD;
          -  Primary chemorefractory disease&#xD;
&#xD;
          -  CML in blast crisis&#xD;
&#xD;
          -  MM with no or minor response to previous treatment&#xD;
&#xD;
          -  Prior treatment with palifermin, or other keratinocyte growth factors&#xD;
&#xD;
          -  Documented hypersensitivity to palifermin, E. coli-derived proteins, or any component&#xD;
             of the product&#xD;
&#xD;
          -  Documented hypersensitivity to Prevenar vaccine or its components&#xD;
&#xD;
          -  Prior allogeneic or tandem PBPC transplantation (no more than 1 previous autologous&#xD;
             transplantation&#xD;
&#xD;
          -  Prior total body irradiation&#xD;
&#xD;
          -  Post thymectomy&#xD;
&#xD;
          -  Major anticipated illness or organ failure incompatible with survival from PBPC&#xD;
             transplantation&#xD;
&#xD;
          -  Active chronic skin disease requiring therapy&#xD;
&#xD;
          -  Active inflammatory bowel disease requiring therapy&#xD;
&#xD;
          -  Active uncontrolled infection&#xD;
&#xD;
          -  Sero-positive HIV&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Active invasive fungal tissue infection (EORTC criteria)&#xD;
&#xD;
          -  30 days or less since receiving an investigational product or device in another&#xD;
             clinical trial&#xD;
&#xD;
          -  Concurrent enrolment in another trial is not permitted unless the purpose is for&#xD;
             long-term follow-up/survival data only, or observational only&#xD;
&#xD;
          -  Chronic pancreatitis or history of acute pancreatitis within 1 year prior to&#xD;
             transplant&#xD;
&#xD;
          -  Psychiatric disorder associated with incompliance&#xD;
&#xD;
          -  Myocardial infarction less than 3 months pre enrolment or EF &lt;30% as measured in&#xD;
             echocardiography/laevoventriculography&#xD;
&#xD;
          -  Infusion of retrovirally or other transduced cells are not permitted.&#xD;
&#xD;
          -  Planned intravenous application of immunoglobulins is contraindicated throughout the&#xD;
             study period.&#xD;
&#xD;
          -  Donor lymphocyte infusions are not allowed.&#xD;
&#xD;
        Donor:&#xD;
&#xD;
          -  A positive HIV or HTLV-1 test or evidence of active/persistent viral hepatitis&#xD;
             infection.&#xD;
&#xD;
          -  Evidence of any other active infection&#xD;
&#xD;
          -  Any medical condition (i.e. insulin-dependent diabetes, cardiovascular disorders,&#xD;
             chronic inflammatory diseases) posing a health risk for peripheral blood stem cell&#xD;
             harvest&#xD;
&#xD;
          -  Hematopoietic or marrow function related disease interfering with the collection of&#xD;
             sufficient numbers of normal progenitor cells&#xD;
&#xD;
          -  Pregnancy or breast-feeding&#xD;
&#xD;
          -  Any malignancy besides basal cell epithelioma or cured malignancy &lt; 5 years ago&#xD;
&#xD;
          -  Psychiatric disorder associated with incompliance&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ruth Seggewiss, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital of Würzburg</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dr Ruth Seggewiss</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2012</verification_date>
  <study_first_submitted>December 10, 2007</study_first_submitted>
  <study_first_submitted_qc>December 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2007</study_first_posted>
  <last_update_submitted>May 9, 2012</last_update_submitted>
  <last_update_submitted_qc>May 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 10, 2012</last_update_posted>
  <responsible_party>
    <name_title>Kim Champion</name_title>
    <organization>EBMT (European Group for Blood and Marrow Transplantation)</organization>
  </responsible_party>
  <keyword>Peripheral blood stem cell transplantation</keyword>
  <keyword>Palifermin</keyword>
  <keyword>Kepivance</keyword>
  <keyword>Prevenar</keyword>
  <keyword>Placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myelogenous, Chronic, BCR-ABL Positive</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

